HK stocks alert | Hansoh Pharma (03692) rises over 3%. The domestic market application for indication adaptation of Alimta for lung cancer adjuvant therapy has been accepted.

Hansoh Pharma (03692) rose more than 3%. As of the time of writing, it rose 3.24% to HKD 17.80, with a turnover of 23.7771 million Hong Kong dollars.

Zhitong FinanceJul 21 23:11 ET

Chinese Drug Regulator Accepts Hansoh Pharmaceutical's NDA for Cancer Adjuvant Therapy Drug

Hansoh Pharmaceutical Group's (HKG:3692) new drug application (NDA) for Ameile, developed by a unit of the company, has been accepted by China's National Medical Products Administration, a Friday

MT NewswiresJul 19 05:55 ET

Hansoh Pharma (03692.HK): The application for marketing approval for the use of Amel in the adjuvant treatment of non-small cell lung cancer with EGFR mutations has been accepted by the National Medical Products Administration.

Hansoh Pharma (03692.HK) announced on July 19 that the Type 1 innovative drug, Amele, developed by its subsidiary, Jiangsu Haosen Pharmaceutical Group Co., Ltd., has applied for market approval for the adjuvant treatment of tumor resection in adult patients with non-small cell lung cancer (NSCLC) carrying the exon 19 deletion or exon 21 (L858R) substitution mutation of epidermal growth factor receptor (EGFR) and tested positive. This application is Amele's third indication and has been accepted by the China National Medical Products Administration.

Gelonghui FinanceJul 19 04:37 ET

Express News | Hansoh Pharmaceutical - New Drug Application of Ameile Accepted by Nmpa

ReutersJul 19 04:32 ET

Brokerage Focus: CITIC Securities expects a turbulent upward trend in the A-share market in the second half of the year.

Jingu finance news | CCB international releases its outlook on Hong Kong stock market strategy for the second half of the year. The Hong Kong stock bear market since 2023 ended in January this year and has entered a shaking bull market. The Chinese fundamentals remain moderately repaired, and the policy tone continues to be based on stability. The chance of issuing strong stimulus policies is small, and the "strong production and weak demand" pattern will persist for a while, with a slight fluctuation in corporate profit recovery. The orderly slowdown of inflation and employment in the United States, along with a moderate economic growth, is expected to result in the earliest Fed rate cut in September this year and marginally benefit Hong Kong stock liquidity. The Hang Seng Index is currently at a historically low valuation level, and listed companies are actively buying back and increasing dividends.

金吾財訊Jul 17 04:51 ET

Shareholders in Hansoh Pharmaceutical Group (HKG:3692) Are in the Red If They Invested Three Years Ago

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But if you try your hand at stock picking, you risk returning less

Simply Wall StJul 12 19:04 ET